If You Invested $1,000 In Inovio Stock At Its COVID-19 Pandemic Low, Here’s How Much You’d Have Now
Investors who bought stocks during the COVID-19 market crash in 2020 have generally experienced some big gains in the past two and a half years.
But there was no question some big-name stocks performed better than others since the pandemic bottom.
Coinbase Discloses Restructuring Plan Amid Macro Headwinds, Pfizer Rebuts Generic Version Of COVID-19 Oral Treatment In China, Microsoft Mulls $10B Investment In ChatGPT Owner: Today’s Top Stories
Benzinga
Coinbase Bows Down To Macro Headwinds, To Let Go Of 950 Employees
Moderna’s Interim Earnings Beat Modestly, Uncertainty Looms Over 2023
Moderna Inc (NASDAQ:MRNA) reported interim FY22 COVID-19 vaccine sales of $18.4 billion against $18-19 billion forecasted in the Q3 earnings…
Israel Based Study Shows Omicron Adapted Vaccine Shots Cut Hospitalization Rates In Elderly
Israel based real-world study shows that omicron-targeted COVID-19 vaccine from Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) reduced hospitalizations among older patients.
Israeli Study Shows Pfizer, Biontech Omicron COVID Booster Cuts Hospitalization in Over 65s
-Reuters
https://www.reuters.com/business/healthcare-pharmaceuticals/israeli-study-finds-omicron-covid-booster-cuts-hospitalization-65-2023-01-09/
Codexis Shares Up Following Reports China Is In Talks For Paxlovid Generic; Codexis In 2022 Announced Agreement With Pfizer To Supply Enzyme For The Manufacture Of Paxlovid
https://www.codexis.com/investors/news-events/press-releases/detail/330/codexis-announces-agreement-with-pfizer-to-supply
Merck Vs. Pfizer: Why Analyst Upgrades One Pharmaceutical Stock, While Downgrading Another
The health care sector held up relatively well in a difficult year for stocks in 2022. On Wednesday, one analyst adjusted his coverage of two large cap pharmaceutical stocks heading into what could be a volatile 2023.